Cambrex Breaks Ground on $30M Milan R&D Facility; Iowa API Plant Engineering Complete
- Cambrex has begun construction on a $30 million R&D facility at its Milan, Italy site, adding analytical development and process R&D capabilities with completion expected in H2 2027.
- The company acquired adjacent land to support future expansion and completed initial engineering studies for a large-scale API manufacturing plant in Charles City, Iowa, with groundbreaking scheduled for late 2026.
Operational Impact
Cambrex's Milan R&D expansion and Iowa API plant groundbreaking in late 2026 add European analytical and U.S. API manufacturing capacity, addressing rising CDMO demand for complex small-molecule development.
Source: Contract Pharma Breaking News RSS